. Author manuscript; available in PMC: 2021 Jan 1.

Published in final edited form as: J Invest Dermatol. 2019 Jul 19;140(1):85–93.e2. doi: 10.1016/j.jid.2019.07.679

Table 3.

Changes in TBR_max by Treatment Group During Randomized Controlled Trial Period

	Ustekinumab (n=22)	Placebo (n=19)
Global change compared with baseline within group
Mean difference^*	−0.102 (0.041)^**	0.144 (0.014)^**
Mean % of change (95% CI)^*	−6.58% (−13.64% to 0.47%); (0.066)	12.07% (3.26% to 20.88%);(0.010)^**
Global change compared with placebo (n=41)
Difference of differences^***	−0.246 (0.001)^**	…
Difference of % change^***	−18.65% (−29.45% to −7.85%); (0.001)^**	…

CI indicates confidence interval; and TBR, target-to-background ratio.

One sample test (P value).

^**

Statistically significant findings.

^***

Difference of differences (P value).

Results with NIH-read images (Primary Analysis).